Prof. Dr. med. Marc Pfister MD FCP
Prof. Dr. med. Marc Pfister MD FCP
Medical Faculty, University of Basel, UKBB
Bestätigte E-Mail-Adresse bei - Startseite
Zitiert von
Zitiert von
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister
Clinical Pharmacology & Therapeutics 85 (5), 513-519, 2009
Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects
B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, ...
Clinical Pharmacology & Therapeutics 85 (5), 520-526, 2009
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
RA DeFronzo, M Hompesch, S Kasichayanula, X Liu, Y Hong, M Pfister, ...
Diabetes care 36 (10), 3169-3176, 2013
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
L Zhang, Y Feng, J List, S Kasichayanula, M Pfister
Diabetes, Obesity and Metabolism 12 (6), 510-516, 2010
Differential immunodiagnosis between cystic hydatid disease and other cross-reactive pathologies.
D Poretti, E Felleisen, F Grimm, M Pfister, F Teuscher, C Zuercher, ...
The American journal of tropical medicine and hygiene 60 (2), 193-198, 1999
Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade
P Ferrari, HP Marti, M Pfister, FJ Frey
Journal of hypertension 20 (1), 125-130, 2002
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398
M Pfister, L Labbé, SM Hammer, J Mellors, KK Bennett, S Rosenkranz, ...
Antimicrobial agents and chemotherapy 47 (1), 130-137, 2003
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
S Kasichayanula, X Liu, M Pe Benito, M Yao, M Pfister, FP LaCreta, ...
British journal of clinical pharmacology 76 (3), 432-444, 2013
Daptomycin is highly efficacious against penicillin-resistant and penicillin-and quinolone-resistant pneumococci in experimental meningitis
P Cottagnoud, M Pfister, F Acosta, M Cottagnoud, L Flatz, F Kühn, ...
Antimicrobial agents and chemotherapy 48 (10), 3928-3933, 2004
Effect of kidney function on drug kinetics and dosing in neonates, infants, and children
F Rodieux, M Wilbaux, JN van den Anker, M Pfister
Clinical pharmacokinetics 54 (12), 1183-1204, 2015
Concepts and challenges in quantitative pharmacology and model-based drug development
L Zhang, M Pfister, B Meibohm
The AAPS journal 10 (4), 552-559, 2008
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy …
S Kasichayanula, X Liu, WC Shyu, W Zhang, M Pfister, SC Griffen, T Li, ...
Diabetes, Obesity and Metabolism 13 (1), 47-54, 2011
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose
TA Leil, Y Feng, L Zhang, A Paccaly, P Mohan, M Pfister
CliniCal pharmaCology & TherapeuTiCs 88 (3), 375-382, 2010
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study
S Kasichayanula, X Liu, W Zhang, M Pfister, FP LaCreta, DW Boulton
Clinical therapeutics 33 (11), 1798-1808, 2011
Model‐based meta‐analysis for comparative efficacy and safety: application in drug development and beyond
JW Mandema, M Gibbs, RA Boyd, DR Wada, M Pfister
Clinical Pharmacology & Therapeutics 90 (6), 766-769, 2011
Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers
WK Fenske, I Schnyder, G Koch, C Walti, M Pfister, P Kopp, M Fassnacht, ...
The Journal of Clinical Endocrinology & Metabolism 103 (2), 505-513, 2018
Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative
C Daniel, R Ziswiler, B Frey, M Pfister, HP Marti
Nephron Experimental Nephrology 8 (1), 52-62, 2000
Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates
M Wilbaux, A Fuchs, J Samardzic, F Rodieux, C Csajka, K Allegaert, ...
The Journal of Clinical Pharmacology 56 (8), 909-935, 2016
Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine
M Zhu, S Kaul, P Nandy, DM Grasela, M Pfister
Antimicrobial agents and chemotherapy 53 (6), 2346-2353, 2009
Modeling and simulation of adherence: approaches and applications in therapeutics
LA Kenna, L Labbé, JS Barrett, M Pfister
The AAPS journal 7 (2), E390-E407, 2005
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20